RESEARCHER PROFILE

Michael E. Nassif

← Back to University of Missouri–Kansas City

M

University of Missouri–Kansas City

Heart Failure Treatment and ManagementMechanical Circulatory Support DevicesDiabetes Treatment and ManagementCardiovascular Function and Risk FactorsCardiomyopathy and Myosin Studies

Michael E. Nassif works in Heart Failure Treatment and Management, Mechanical Circulatory Support Devices, Diabetes Treatment and Management, Cardiovascular Function and Risk Factors, Cardiomyopathy and Myosin Studies. Recorded institutional associations include Brigham and Women's Hospital, Jena University Hospital, Saint Luke's Hospital.

216Publications
6,803Citations
40H-index

ORCID

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

    2022 · 939 citations

  2. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial

    2021 · 616 citations

  3. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction

    2019 · 423 citations

  4. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy

    2024 · 327 citations

  5. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure

    2021 · 281 citations

  6. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial

    2022 · 245 citations

  7. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial

    2021 · 243 citations

  8. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial

    2022 · 230 citations

  9. Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction

    2017 · 201 citations

  10. Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial

    2022 · 142 citations

  11. Beta-Blocker Use and Heart Failure Outcomes in Mildly Reduced and Preserved Ejection Fraction

    2023 · 121 citations

  12. Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure

    2018 · 108 citations

  13. Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF

    2022 · 103 citations

  14. Intra-Aortic Balloon Counterpulsation in Patients With Chronic Heart Failure and Cardiogenic Shock: Clinical Response and Predictors of Stabilization

    2015 · 102 citations

  15. Relationship Between Anticoagulation Intensity and Thrombotic or Bleeding Outcomes Among Outpatients With Continuous-Flow Left Ventricular Assist Devices

    2016 · 100 citations

  16. Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial

    2021 · 99 citations

  17. In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction

    2021 · 97 citations

  18. Clinical outcomes associated with INTERMACS-defined right heart failure after left ventricular assist device implantation

    2016 · 92 citations

  19. Systolic blood pressure on discharge after left ventricular assist device insertion is associated with subsequent stroke

    2014 · 90 citations

  20. Usefulness of Psoas Muscle Area Determined by Computed Tomography to Predict Mortality or Prolonged Length of Hospital Stay in Patients Undergoing Left Ventricular Assist Device Implantation

    2016 · 87 citations

  21. Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial

    2022 · 81 citations

  22. Pre-Operative Right Ventricular Dysfunction Is Associated With Gastrointestinal Bleeding in Patients Supported With Continuous-Flow Left Ventricular Assist Devices

    2015 · 77 citations

  23. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy

    2025 · 77 citations

  24. Systemic inflammatory response syndrome after transcatheter or surgical aortic valve replacement

    2015 · 72 citations

  25. Validation of the Kansas City Cardiomyopathy Questionnaire in Symptomatic Obstructive Hypertrophic Cardiomyopathy

    2022 · 71 citations

← Return to the university profile